Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of vorasidenib versus placebo in residual or recurrent IDH-mutant grade 2 glioma
2019-002481-13Phase 3Active
- Sponsor
- Servier
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioma comparing vorasidenib with placebo (2 arms). Primary endpoint: Radiographic progression-free survival. Started May 2020; status: active.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on 2019-002481-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002481-13.